caspase

(redirected from Caspases)
Also found in: Dictionary, Thesaurus, Medical.
Related to Caspases: apoptosis, cytochrome c, Bcl-2

caspase

[′kas‚pās]
(cell and molecular biology)
Any of a family of intracellular proteins that mediate apoptosis.
References in periodicals archive ?
Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics.
Caspase activation was significantly elevated in patients with definitive NASH, with median cytokeratin-18 levels of 767 U/L, compared with 202 U/L in patients with simple steatosis.
Binding of Fas ligand (FasL) to Fas results in caspase 8 activation, which in turn activates and cleaves B cell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) interacting domain (Bid), a member of the Bcl-2 family.
The publication, "Protection Against TNF-Induced Parenchymal Cell Apoptosis during Endotoxemia by a Novel Caspase Inhibitor in Mice," appeared in the November 15, 2000 issue of Toxicology and Applied Pharmacology (volume 169, pp.
They confirmed by chemical methods that the fluorescent probes were indeed binding to caspases.
therapeutic applications focused on inhibiting caspase activity as potential
For analysis of the levels of cyt c, caspase-3, caspase -9, and p-ERK, the cells were rinsed with ice-cold PBS and lysed with lysis buffer [1% Triton, 1% Nonidet P-40, 0.
Alnmeri, Thomas Jefferson University, Philadelphia, PA) has been reported to inhibit the caspase cascade (5).
Reed and his colleagues, who describe their work in the January Cancer Cell, knew from previous studies that a protein called X chromosome-linked inhibitor of apoptosis (XIAP) binds to and blocks the action of several different caspases.
Antisoma plc (London, England; 44-20-8799-8200), the United Kingdom-based biopharmaceutical company specializing in the development of products for the treatment of cancer, announced that it has been granted a British patent for fusion proteins consisting of a tumor targeting portion such as an antibody, with a constitutively active caspase enzyme.
LGLS) today announced that the companies have entered into an exclusive license agreement focused on the development of caspase inhibitors for the treatment of fibrotic diseases.